Ticagrelor
Bleeding
Icahn School of Medicine at Mount SinaiSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Bleeding cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivaroxaban Icahn School of Medicine at Mount Sinai | Phase 4 | BBB |
Plavix Icahn School of Medicine at Mount Sinai | Phase 4 | BBB |
Dabigatran St. Antonius Hospital | Phase 4 | BBB |
WARFARIN China National Center for Cardiovascular Diseases | Phase 4 | BBB |
Acetylsalicylic Acid China National Center for Cardiovascular Diseases | Phase 4 | BBB |
View all 20 →
Same molecule, other indications
Ticagrelor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →